These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

654 related items for PubMed ID: 21452978

  • 1. Reaction-driven de novo design, synthesis and testing of potential type II kinase inhibitors.
    Schneider G, Geppert T, Hartenfeller M, Reisen F, Klenner A, Reutlinger M, Hähnke V, Hiss JA, Zettl H, Keppner S, Spänkuch B, Schneider P.
    Future Med Chem; 2011 Mar; 3(4):415-24. PubMed ID: 21452978
    [Abstract] [Full Text] [Related]

  • 2. Identification of novel polo-like kinase 1 inhibitors by a hybrid virtual screening.
    Lu S, Sun SL, Liu HC, Chen YD, Yuan HL, Gao YP, Yang P, Lu T.
    Chem Biol Drug Des; 2012 Aug; 80(2):328-39. PubMed ID: 22583481
    [Abstract] [Full Text] [Related]

  • 3. Design, synthesis, and evaluation of non-ATP-competitive small-molecule Polo-like kinase 1 (Plk1) inhibitors.
    Chen DX, Huang J, Liu M, Xu YG, Jiang C.
    Arch Pharm (Weinheim); 2015 Jan; 348(1):2-9. PubMed ID: 25430493
    [Abstract] [Full Text] [Related]

  • 4. Drugs by numbers: reaction-driven de novo design of potent and selective anticancer leads.
    Spänkuch B, Keppner S, Lange L, Rodrigues T, Zettl H, Koch CP, Reutlinger M, Hartenfeller M, Schneider P, Schneider G.
    Angew Chem Int Ed Engl; 2013 Apr 22; 52(17):4676-81. PubMed ID: 23166089
    [Abstract] [Full Text] [Related]

  • 5. Structures of the wild-type and activated catalytic domains of Brachydanio rerio Polo-like kinase 1 (Plk1): changes in the active-site conformation and interactions with ligands.
    Elling RA, Fucini RV, Romanowski MJ.
    Acta Crystallogr D Biol Crystallogr; 2008 Sep 22; 64(Pt 9):909-18. PubMed ID: 18703838
    [Abstract] [Full Text] [Related]

  • 6. Identification of 2-anilino-9-methoxy-5,7-dihydro-6H-pyrimido[5,4-d][1]benzazepin-6-ones as dual PLK1/VEGF-R2 kinase inhibitor chemotypes by structure-based lead generation.
    Egert-Schmidt AM, Dreher J, Dunkel U, Kohfeld S, Preu L, Weber H, Ehlert JE, Mutschler B, Totzke F, Schächtele C, Kubbutat MH, Baumann K, Kunick C.
    J Med Chem; 2010 Mar 25; 53(6):2433-42. PubMed ID: 20170163
    [Abstract] [Full Text] [Related]

  • 7. Pharmacophore modeling and virtual screening for designing potential PLK1 inhibitors.
    Wang HY, Cao ZX, Li LL, Jiang PD, Zhao YL, Luo SD, Yang L, Wei YQ, Yang SY.
    Bioorg Med Chem Lett; 2008 Sep 15; 18(18):4972-7. PubMed ID: 18762425
    [Abstract] [Full Text] [Related]

  • 8. Design and synthesis of 2-amino-pyrazolopyridines as Polo-like kinase 1 inhibitors.
    Fucini RV, Hanan EJ, Romanowski MJ, Elling RA, Lew W, Barr KJ, Zhu J, Yoburn JC, Liu Y, Fahr BT, Fan J, Lu Y, Pham P, Choong IC, VanderPorten EC, Bui M, Purkey HE, Evanchik MJ, Yang W.
    Bioorg Med Chem Lett; 2008 Oct 15; 18(20):5648-52. PubMed ID: 18793847
    [Abstract] [Full Text] [Related]

  • 9. Selectivity-determining residues in Plk1.
    Kothe M, Kohls D, Low S, Coli R, Rennie GR, Feru F, Kuhn C, Ding YH.
    Chem Biol Drug Des; 2007 Dec 15; 70(6):540-6. PubMed ID: 18005335
    [Abstract] [Full Text] [Related]

  • 10. Small-molecular, non-peptide, non-ATP-competitive polo-like kinase 1 (Plk1) inhibitors with a terphenyl skeleton.
    Mita Y, Noguchi-Yachide T, Ishikawa M, Hashimoto Y.
    Bioorg Med Chem; 2013 Feb 01; 21(3):608-17. PubMed ID: 23276450
    [Abstract] [Full Text] [Related]

  • 11. Depsides isolated from the Sri Lankan lichen Parmotrema sp. exhibit selective Plk1 inhibitory activity.
    Williams DE, Loganzo F, Whitney L, Togias J, Harrison R, Singh MP, McDonald LA, Kathirgamanathar S, Karunaratne V, Andersen RJ.
    Pharm Biol; 2011 Mar 01; 49(3):296-301. PubMed ID: 21281249
    [Abstract] [Full Text] [Related]

  • 12. Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.
    Rheault TR, Donaldson KH, Badiang-Alberti JG, Davis-Ward RG, Andrews CW, Bambal R, Jackson JR, Cheung M.
    Bioorg Med Chem Lett; 2010 Aug 01; 20(15):4587-92. PubMed ID: 20594842
    [Abstract] [Full Text] [Related]

  • 13. Discovery of Non-ATP-Competitive Inhibitors of Polo-like Kinase 1.
    Yun T, Qin T, Liu Y, Lai L.
    ChemMedChem; 2016 Apr 05; 11(7):713-7. PubMed ID: 27061239
    [Abstract] [Full Text] [Related]

  • 14. Identification and validation of a potent type II inhibitor of inactive polo-like kinase 1.
    Keppner S, Proschak E, Schneider G, Spänkuch B.
    ChemMedChem; 2009 Nov 05; 4(11):1806-9. PubMed ID: 19746360
    [No Abstract] [Full Text] [Related]

  • 15. Design, synthesis, and biological evaluation of polo-like kinase 1/eukaryotic elongation factor 2 kinase (PLK1/EEF2K) dual inhibitors for regulating breast cancer cells apoptosis and autophagy.
    Pan Z, Chen Y, Liu J, Jiang Q, Yang S, Guo L, He G.
    Eur J Med Chem; 2018 Jan 20; 144():517-528. PubMed ID: 29288948
    [Abstract] [Full Text] [Related]

  • 16. Imidazopyridine derivatives as potent and selective Polo-like kinase (PLK) inhibitors.
    Sato Y, Onozaki Y, Sugimoto T, Kurihara H, Kamijo K, Kadowaki C, Tsujino T, Watanabe A, Otsuki S, Mitsuya M, Iida M, Haze K, Machida T, Nakatsuru Y, Komatani H, Kotani H, Iwasawa Y.
    Bioorg Med Chem Lett; 2009 Aug 15; 19(16):4673-8. PubMed ID: 19589677
    [Abstract] [Full Text] [Related]

  • 17. In silico identification of putative bifunctional Plk1 inhibitors by integrative virtual screening and structural dynamics approach.
    Shafique S, Bibi N, Rashid S.
    J Theor Biol; 2016 Jan 07; 388():72-84. PubMed ID: 26493360
    [Abstract] [Full Text] [Related]

  • 18. Structure of the catalytic domain of human polo-like kinase 1.
    Kothe M, Kohls D, Low S, Coli R, Cheng AC, Jacques SL, Johnson TL, Lewis C, Loh C, Nonomiya J, Sheils AL, Verdries KA, Wynn TA, Kuhn C, Ding YH.
    Biochemistry; 2007 May 22; 46(20):5960-71. PubMed ID: 17461553
    [Abstract] [Full Text] [Related]

  • 19. Genetic approach to evaluate specificity of small molecule drug candidates inhibiting PLK1 using zebrafish.
    Zhong H, Xin S, Zhao Y, Lu J, Li S, Gong J, Yang Z, Lin S.
    Mol Biosyst; 2010 Aug 22; 6(8):1463-8. PubMed ID: 20625580
    [Abstract] [Full Text] [Related]

  • 20. Identification of a high affinity selective inhibitor of Polo-like kinase 1 for cancer chemotherapy by computational approach.
    Kumar M, Pydi SP, Sharma S, Singh TP, Kaur P.
    J Mol Graph Model; 2014 Jun 22; 51():104-12. PubMed ID: 24879322
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.